Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corporation

Texas Biomedical Research Institute focuses on basic and translational research to advance human health and eradicate infectious diseases. It has a history of developing significant therapies and vaccines.

Texas Biomedical Research Institute

Adaptive Biotechnologies utilizes the adaptive immune system to develop diagnostics and therapeutics, focusing on immune medicine and clinical diagnostics.

Metric
Company Name	Adaptive Biotechnologies Corporation	Texas Biomedical Research Institute
Symbol	ADPT
MSH ID	COM:ADAPTIVEBIOTECH	ORG:TXBIOMED
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Research and Development
Country	US	US
Stage
Employee Count	709
Website	adaptivebiotech.com	txbiomed.org
LinkedIn
Founders

Metric
Market Cap	515.79M
Enterprise Value
Monthly Web Traffic	7.23K
Web Traffic Growth	-0.12
Valuation
Raised Capital	125M

Metric
Revenue	170.28M
Revenue (LTM)
Revenue (NTM)
Gross Profit	72.49M
EBITDA	-179.38M
Operating Income	-201.61M
Net Income	-225.25M
EPS	-1.56
Diluted EPS	-1.56
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.54
Operating Profit Margin	-1.09
EBITDA Margin	-1.05
Net Profit Margin	-1.23
Return on Equity	-0.62
Return on Assets	-0.35
Return on Capital Employed	-0.35

COM:ADAPTIVEBIOTECH

Adaptive Biotechnologies

Last Close

4.37

22/11 21:00

Market Cap

515.79M

Beta: -

Volume Today

2.30M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-2.72
P/B Ratio	1.38
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.82
EV Multiple	-1.23

Metric
Days Sales Outstanding	63.40
Days Payables Outstanding	22.56
Days Inventory Outstanding	65.15
Operating Cycle	148.68
Cash Conversion Cycle	113.88
Asset Turnover	0.29

Metric
Operating Cash Flow	-156.32M
Free Cash Flow	-167.02M
Cash Flow to Debt	-0.91
Operating Cash Flow/Sales	-0.77
Free Cash Flow Yield	-0.34

Metric
Cash & Equivalents	65.06M
Accounts Receivable	2.03M
Inventory	14.45M
Goodwill	118.97M
Debt to Capitalization	0.37
Debt to Assets	0.14
Current Ratio	4.67
Quick Ratio	4.38

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.34
R&D to Revenue	0.69
SG&A to Revenue	0.48